Uveitis- Market Insights, Epidemiology, and Market Forecast-2028
SKU ID : DEL-14679806 | Publishing Date : 01-Sep-2019 | No. of pages : 237
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Uveitis from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2028
Uveitis - Disease Understanding and Treatment Algorithm
The Uveitis market report gives a thorough understanding of the Uveitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Uveitis in the US, Europe, and Japan.
The Uveitis epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Uveitis in 7MM, Total Diagnosed Prevalence of Uveitis in 7MM, Gender-specific Diagnosed Prevalence of Uveitis, Age-specific Diagnosed Prevalence of Uveitis, Type Specific Diagnosed Prevalence of Uveitis, Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location, and Grade-specific Diagnosed Prevalence of Uveitis) scenario of Uveitis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.
According to , the total number of diagnosed prevalent population of Uveitis in 7MM was found to be approximately 737,800 in the year 2017.
Uveitis Drug Chapters
This segment of the Uveitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current management of uveitis solely depends on corticosteroids, immunosuppressants, and biologics. Corticosteroids are recommended as first-line of therapies for the treatment of uveitis. The approved and upcoming therapies that fall under this category includes Iluvien, EGP-437, and Suprachoroidal CLS-TA. Corticosteroids accounts for the 65.44% of the total Uveitis market in 2017. Immunosuppressants are the second-line of treatment therapy. The appropriate treatment and choice of immunosuppressive therapy of Uveitis depend on both the extent and severity of the inflammatory process. Biologic response modifiers, or so-called biologics, are the relatively new medications studied and used for the treatment of noninfectious uveitis and other ocular inflammatory diseases. Biologic therapy can be an alternative in patients with inadequate response to or tolerance of conventional immunotherapy.
The horizon currently appears very bright, given the many therapeutic agents and approaches for uveitis and ocular inflammatory diseases. Different classes of agents, from calcineurin inhibitors to mTOR inhibitors and IL inhibitors, among others, are being evaluated. In addition, delivery systems such as iontophoresis will also allow novel methods of safe and effective administration of pharmacologic agents. Hopefully, such efforts will lead to therapeutic options for our patients in the near future.
Launch of emerging therapies, such as Sirolimus (for Non-Infectious Uveitis of the Posterior Segment (NIU-PS)), EGP-437 (for Non-Infectious Anterior Uveitis), Sarilumab (for Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)), Suprachoroidal CLS-TA(Triamcinolone Acetonide) (for Macular edema associated with non-infectious uveitis), LFG316 (Non-infectious Intermediate Uveitis; Non-infectious Posterior Uveitis; Non-infectious Panuveitis), LME636 ( Anterior Acute Uveitis) shall further create a positive impact on the market.
Apart from the pharmacological therapies few companies are working in the development of gene therapy which can provide a cure to the disease.
Uveitis Market Outlook
The Uveitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to , the market of Uveitis in 7MM was found to be approximately USD 1027.0 million in 2017 and is expected to increase from 2017-2028.
Uveitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Uveitis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Uveitis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Uveitis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This report will help to develop Business Strategies by understanding the trends shaping and driving Uveitis Infections market
• Organize sales and marketing efforts by identifying the best opportunities for Uveitis market
• To understand the future market competition in the Uveitis market.